Decramer Marc
Respiratory Division, University Hospital Katholieke Universiteit, Leuven, Belgium.
Clin Invest Med. 2008 Oct 1;31(5):E312-8. doi: 10.25011/cim.v31i5.4882.
COPD is a disease that is not confined to the airways and the lungs, but also produces systemic consequences. Muscle weakness is one of these. It is produced by a multitude of factors including deconditioning, systemic inflammation, oxidative stress, nutritional imbalance, reduced anabolic status, systemic corticosteroids, hypoxemia, hypercapnia, electrolyte disturbances, cardiac failure. The most important factors appear to be inactivity and systemic inflammation. Inactivity was shown to be present in patients with COPD from early in the course of the disease on. Systemic inflammation was shown to be predominantly present during COPD exacerbations. IL-6 has the propensity to reduce muscle function in experimental animals. At present there is no evidence of local production of cytokines in the muscle in patients with COPD. Muscle weakness is also important in the clinical course of the disease as it is associated with exercise intolerance, reduced quality of life, enhanced utilization of health care resources and reduced survival. Rehabilitation is the best treatment for muscle weakness and deconditioning in patients with COPD. Indeed, it is the intervention with the largest effect on health status and exercise capacity in these patients. Several factors that may enhance the effects of rehabilitation have been studied. These include: growth hormone/ IGF-I, anabolic steroids, clenbuterol, creatine, anti-cytokine treatment, erythropoietin, oxygen, non-invasive mechanical ventilation and electrical stimulation. Recently, the potential of protease-inhibitors in reversing deconditioning-induced muscle dysfunction was demonstrated. Adjuncts are potentially particularly useful in patients who do not respond to a rehabilitation programme. Analysis of large d-bases demonstrated that about one third of the patients does not respond to rehabilitation. A follow-up study suggests that decline in exercise capacity after a rehabilitation programme is particularly present in these patients and not in the patients with a clear initial response. A better understanding of the factors controlling the response to rehabilitation, may lead to significant advances in this field.
慢性阻塞性肺疾病(COPD)是一种不仅局限于气道和肺部的疾病,还会产生全身性后果。肌肉无力就是其中之一。它由多种因素导致,包括身体失健、全身炎症、氧化应激、营养失衡、合成代谢状态降低、全身性皮质类固醇、低氧血症、高碳酸血症、电解质紊乱、心力衰竭。最重要的因素似乎是缺乏活动和全身炎症。研究表明,从疾病早期开始,COPD患者就存在身体缺乏活动的情况。全身炎症主要在COPD急性加重期出现。白细胞介素-6(IL-6)在实验动物中具有降低肌肉功能的倾向。目前没有证据表明COPD患者的肌肉中有细胞因子的局部产生。肌肉无力在该疾病的临床进程中也很重要,因为它与运动不耐受、生活质量下降、医疗资源利用增加和生存率降低有关。康复治疗是COPD患者肌肉无力和身体失健的最佳治疗方法。事实上,它是对这些患者健康状况和运动能力影响最大的干预措施。已经研究了几种可能增强康复效果的因素。这些因素包括:生长激素/胰岛素样生长因子-I(IGF-I)、合成代谢类固醇、克仑特罗、肌酸、抗细胞因子治疗、促红细胞生成素、氧气、无创机械通气和电刺激。最近,蛋白酶抑制剂在逆转失健引起的肌肉功能障碍方面的潜力得到了证实。辅助治疗对于对康复计划无反应的患者可能特别有用。对大型数据库的分析表明,约三分之一的患者对康复治疗无反应。一项随访研究表明,康复计划后运动能力下降在这些患者中尤为明显,而在最初有明显反应的患者中则不存在。更好地理解控制康复反应的因素,可能会在这一领域取得重大进展。